Imidazole compounds

A compound of formula (II):

• wherein
• W is, independently from other member and substituent assignments, N;
• X is, independently from other member and substituent assignments, CR9;
• Y is, independently from other member and substituent assignments, O, NR10, or CR10R11;
• Z is, independently from other member and substituent assignments, N or CR12;
• n is, independently from other member and substituent assignments, 0, 1, or 2;
• each of R1-2 is, independently from other member and substituent assignments, —H, —CF3, —C1-6alkyl, —C3-6cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl;
• or, R1 and R2 taken together with the carbon atoms to which they are attached form a cyclic structure Cyc1 selected from 5- or 6-membered carbocycle, and 5- or 6-membered heterocycle with 1 heteroatom, wherein said cyclic structure Cyc1 is, independently from other substituent assignments, substituted with 0, 1, or 2 substituents selected from —C1-3alkyl, halo, hydroxy, amino, and —C1-3alkoxy;
• each of R3-4 and R9 is, independently from other member and substituent assignments, —H, —C1-6alkyl, halo, —CF3, —OCF3, —ORc, —SRc, —S(O)Rc, —SO2Rc, C1-4alkoxy, cyano, nitro, —C(O)NRaRb, —C(O)phenyl, —C(O)C1-6alkyl, —S(O)C1-4alkyl, or —SO2C1-4alkyl;
• or, R3 and R4 taken together with the carbon atoms to which they are attached form a cyclic structure Cyc2 selected from aryl, 5- or 6-membered carbocycle, and 5- or 6-membered heterocycle with 1 or 2 heteroatoms, wherein said cyclic structure Cyc2 is, independently from other substituent assignments, substituted with 0, 1, or 2 substituents selected from —C1-3alkyl, halo, hydroxy, amino, and —C1-3alkoxy;
• wherein each of Ra, Rb and Rc is, independently from other substituent assignments, selected from H, C1-4alkyl, C3-6cycloalkyl, phenyl, (C3-6cycloalkyl)C1-2alkyl-, benzyl and phenethyl, or Ra and Rb taken together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring HetCyc1, wherein said ring HetCyc1 has 0 or 1 additional heteroatoms selected from O, S, >NH and >NC1-6alkyl, and wherein any phenyl, phenethyl, benzyl, alkyl or cycloalkyl moiety in any of said R1-4, Ra, Rb, Rc, and said ring HetCyc1 is optionally, and independently from other substituent assignments, substituted with 1, 2 or 3 substituents selected from C1-3alkyl, halo, hydroxy, amino, and C1-3alkoxy;
• R5 is, independently from other member and substituent assignments, —H, —C1-6alkyl, —C1-4alkoxy, or hydroxy;
• each of R6 and R7 is, independently from other member and substituent assignments, —H or —C1-6alkyl, or R6 and R7 taken together form a 5-6 membered cyclic structure Cyc3, wherein said cyclic structure Cyc3 is a 5- or 6-membered carbocycle or a 5- or 6-membered heterocycle with 1 or 2 heteroatoms, and wherein said cyclic structure Cyc3 is, independently from other substituent assignments, substituted with 0, 1, or 2 substituents selected from —C1-3alkyl, halo, hydroxy, amino, and —C1-3alkoxy;
• R8 is, independently from other member and substituent assignments, —H or —C1-4alkyl;
• each of R10 and R11 is, independently from other member and substituent assignments, —H or —C1-4alkyl;
• or, when Y is CR10R11, R10 and R11 taken together with the carbon member to which they are attached form an optionally substituted cyclic structure Cyc4, wherein said cyclic structure Cyc4 is a 3- to 6-membered carbocycle or a 3- to 6-membered non-aromatic heterocycle with 0 or 1 additional heteroatoms, or CR10R11 is C═O;
• R12 is, independently from other member and substituent assignments, —H, —C1-4alkyl, hydroxy, or —C1-4alkoxy;
• an enantiomer, diastereomer, racemate thereof, or a pharmaceutically acceptable salt, amide or ester thereof;
• with the following provisos:
• when Y is O or NR10, then Z is CR12 and R5 is not hydroxy or —C1-4alkoxy;
• when Z is N, Y is CR10R11;
• when R1 and R2 are both —H, Y is CH2, and R8 is methyl, then R5 is not hydroxy.